Source: Health Times.com
On November 26, local time, the World Health Organization has listed the new coronavirus variant strain (B.1.1.529 variant) discovered in South Africa as a variant that "needs attention" and named it the Greek name Omicron (Omicron).
The World Health Organization said that after sequencing the new coronavirus mutant strain B.1.1.529, it found that it has more mutations than all previous new coronavirus mutant strains. There are 32 mutation mutations found, and 15 mutations in the Delta mutant strain.
The article published on "Nature" on November 25 stated that the Omicron variant contains a large number of mutations in the spike protein region recognized by the antibody, which may weaken the effectiveness of the vaccine. Penny Moore, a virologist at the University of Witwatersland, Johannesburg, South Africa, said that breakthrough infections have occurred in South Africa's people vaccinated with Johnson & Johnson, Pfizer-BioNTech and Oxford-AstraZeneca vaccines.
On November 27, the research team of the Children's Hospital of Rome, Italy released the world's first picture of the new variant strain Omickron of the new coronavirus
Yang Zhanqiu, professor of the Institute of Virology, Department of Medicine, Wuhan University, said in an interview with the Global Times on November 26 that although there are many mutations in B.1.1.529, it is still not a new subtype, and has not reached the point of immune escape and vaccine failure. The existing new coronavirus vaccine still has a certain protective effect at present.
Does the vaccine also need to be updated in the face of the new crown mutant strain? Various vaccine companies responded.
Sinovac Biotech: It has started the collection of mutant strain information and samples
People's Daily Health Client learned from the new crown vaccine manufacturer Sinovac Co., Ltd. on the evening of November 27 that the development of the new crown inactivated vaccine against Gamma and Delta strains has been carried out. Sinovac is highly concerned about information related to the Omicron variant of the new coronavirus. It has initiated the active collection and acquisition of information and samples related to the new variant through a global partner network. It will conduct evaluation and research as soon as possible to understand the impact of the Omicron strain on the existing inactivated vaccines and the necessity of developing a variant vaccine.
As of now, China's Sinovac has supplied more than 2.2 billion doses of new crown vaccine to nearly 50 countries and regions around the world, including more than 1.3 billion doses in China and more than 900 million doses abroad. Sinovac said that it has mature vaccine production processes and large-scale production capabilities. If necessary, the company can quickly advance the development and large-scale production of new vaccines, and be able to ensure vaccine demand.
Pfizer and Bruce Entai: The effectiveness of the vaccine on the mutant strain has been started, and the results will be released at the latest 2 weeks
According to Fox Business Network, on November 26 local time, Bruce Entai (BioNtech) and Pfizer said that the effectiveness of the mRNA new crown vaccine on the omicron variant strain has been started, and the results will be released within two weeks at the latest.
Pfizer said that if a vaccine escape variant appears, the two companies are expected to be able to develop and produce specific vaccines for the variant within about 100 days.
Johnson & Johnson: It is testing the effectiveness of the vaccine against the new variant
According to Fox Business Network on November 26 local time, Johnson & Johnson responded in an email that the company is testing the effectiveness of its new crown vaccine against the B.1.1.529 variant.
Johnson & Johnson's new crown vaccine (Jassen) is an adenovirus vector vaccine. A spokesperson wrote: "We are closely monitoring the emerging omicron variant strains and are already testing the effectiveness of its vaccine on the fast-spreading new variants first discovered in southern Africa."
AstraZeneca: The impact of variant strains on vaccine and antibody combination drugs is being studied
According to the Global News Network, AstraZeneca said on November 26 local time that it is studying the impact of the novel coronavirus variants that are rapidly spreading in South Africa on its new coronavirus vaccine and antibody combination drugs. AstraZeneca's new crown vaccine is an adenovirus vector vaccine. AstraZeneca said the company is conducting research in two southern African countries, Botswana and Swatini, to collect data, which will allow the company to collect real-world data against the variant strain.
Modna: It is testing the ability to neutralize the mutant strain of the current vaccine dose
According to The Paper, on November 26 local time, Moderna announced a solution strategy for the Omicron variant and said that the company is quickly working to test the ability to neutralize the mutant strain of the current vaccine dose, and data is expected to be provided in the next few weeks.
Modner's 50 microgram mRNA-1273 has been granted emergency use authorization in the United States for adults aged 18 and above, and obtained emergency use authorization for enhanced needles on November 19 local time. Moderna said that if the currently authorized 50 microgram mRNA-1273 booster dose is proven to be insufficient to enhance immunity against the omicron variant, it will be responded from three levels in the future: First, Moderna has tested the safety and immunogenicity of higher doses of mRNA-1273 (100 microgram) enhancer in healthy adults. 2. Two multivalent enhancement vaccine candidates, including mRNA-1273.211 and mRNA-1273.213, have been studied, which aim to predict mutations, such as those occurring in Omicron variants. Third, the candidate product mRNA-1273.529 for Omicron variants will be rapidly advanced.
Novavax: Research on the new crown vaccine against variants has begun
Reuters reported on November 27 that Novavax said that the company has begun to study vaccines against the B.1.1.529 new crown variant strain and will prepare the vaccine for testing and production in the next few weeks. "Preliminary work will take several weeks," a spokesperson for the company said.
The company's vaccine is a recombinant protein subunit vaccine. Novavax also submitted an emergency use list (EUL) to the World Health Organization (WHO).
This article comes from [Health Times Network] and only represents the author's views. The national party media information public platform provides information release and dissemination services.
ID: jrtt
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-